Trials / Completed
CompletedNCT04668352
A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,024 (actual)
- Sponsor
- Restorbio Inc. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
To determine if RTB101 as compared to placebo decreases the percentage of subjects with clinically symptomatic respiratory illness (with or without an associated laboratory-confirmed pathogen) through Week 16.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dactolisib | TORC1 inhibitor |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2019-12-02
- Completion
- 2019-12-02
- First posted
- 2020-12-16
- Last updated
- 2021-06-23
- Results posted
- 2021-06-23
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04668352. Inclusion in this directory is not an endorsement.